Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide

Nitin T. Supekar, Vani Lakshminarayanan, Chantelle J. Capicciotti, Anju Sirohiwal, Cathy S. Madsen, Margreet A. Wolfert, Peter A. Cohen, Sandra J. Gendler, Geert Jan Boons

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


A fully synthetic MUC1-based cancer vaccine was designed and chemically synthesized containing an endogenous helper T-epitope (MHC class II epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC). It also activated cytotoxic T-lymphocytes. Collectively, the immunological data demonstrate engagement of helper T-cells in immune activation. A synthetic methodology was developed for a penta-glycosylated MUC1 glycopeptide, and antisera of mice immunized by the new vaccine recognized such a structure. Previously reported fully synthetic MUC1-based cancer vaccines that elicited potent immune responses employed exogenous helper T-epitopes derived from microbes. It is the expectation that the use of the newly identified endogenous helper T-epitope will be more attractive, because it will activate cognate CD4+ T-cells that will provide critical tumor-specific help intratumorally during the effector stage of tumor rejection and will aid in the generation of sustained immunological memory.

Original languageEnglish (US)
Pages (from-to)121-125
Number of pages5
Issue number2
StatePublished - Jan 18 2018


  • T-epitope
  • cancer
  • endogenous helper
  • glycopeptide
  • multicomponent vaccine

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Organic Chemistry


Dive into the research topics of 'Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide'. Together they form a unique fingerprint.

Cite this